Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Inhaled Antibiotics Market Valued at Present and by 2029?
The market size of inhaled antibiotics has seen a robust growth in the past few years. The market value is expected to increase from $1.56 billion in 2024 to $1.66 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%. Consequently, this growth during the historic period is the result of regulation support and approval, the transition from systemic to targeted delivery, escalation in antibiotic resistance, and an upsurge in respiratory infections.
The market for inhaled antibiotics is anticipated to witness robust expansion in the coming years, ballooning to “$2.33 billion by 2029 with an annual compounded growth rate (CAGR) of 8.8%. This projected growth over the forecast period can be associated with the increasing funding in research & development, broadening of clinical uses, amplified focus on individualized treatments, advancements in medicine formulations, and persistent concerns over antibiotic resistance. In the same forecast period, we can expect ongoing innovations in formulas, a more patient-aligned strategy, augmented research in respiratory health, a shift towards more targeted therapies and progress in drug delivery systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8738&type=smp
#What Drivers Are Influencing Growth In The Inhaled Antibiotics Market?
The escalating prevalence of respiratory illnesses is expected to drive the expansion of the inhaled antibiotics market. Diseases affecting the lungs and airways, thereby impeding routine breathing, are classified as respiratory ailments. In patients suffering from cystic fibrosis, inhaled antibiotics improve lung efficiency, delay the degradation of lung functions, prolong the intervals between exacerbations, and improve the overall quality of life. For example, in the first half of 2023, the UK Health Security Agency, a government organization based in the UK, reported a 7% increase in Tuberculosis (TB) cases in England compared to the same period in 2022, according to the September 2023 reports. As a result, the inhaled antibiotics market is being propelled by the upsurge in respiratory disease occurrences.
What Are The Main Segments Identified In The Inhaled Antibiotics Market Research?
The inhaled antibiotics market covered in this report is segmented –
1) By Product Type: Aerosol Or Metered Dose Inhaler, Dry Powder Formulation, Spray, Other Types
2) By Application: Pneumonia, Asthma, Bronchitis, Other Applications
3) By End-User: Hospitals, Other End Users
Subsegments:
1) By Aerosol Or Metered Dose Inhaler: Levofloxacin Inhalation Solution, Tobramycin Inhalation Solution, Aztreonam Inhalation Solution
2) By Dry Powder Formulation: Dry Powder Tobramycin, Dry Powder Colistin
3) By Spray: Antibiotic Nasal Sprays, Inhaled Antibiotic Solutions
4) By Other Types: Nebulized Antibiotics, Intranasal Antibiotics
What Long-Term Trends Are Likely To Affect The Inhaled Antibiotics Market?
There is a growing trend in the inhaled antibiotics market towards increased investment in the research and development of these drugs. Many leading pharmaceutical firms are financially supporting the creation of inhaled antibiotics in order to maintain their competitive stance. For example, in August 2023, Spexis AG, a biopharmaceutical company based in Switzerland, pledged $2.5 million to fund the commercialisation of colistimethate sodium in the U.S. – an inhaled antibiotic designed to treat cystic fibrosis patients with Pseudomonas aeruginosa infections. The investment helps underpin expected commercialisation costs of around $90 million, with the potential for peak sales to reach as high as $300 million. Additionally, it facilitates the kick-off of the Phase III trial for the antibiotic’s safety and effectiveness in treating cystic fibrosis.
Which Companies Play A Key Role In The Development Of The Inhaled Antibiotics Market?
Major companies operating in the inhaled antibiotics market are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Novartis AG, Bayer AG, Pfizer Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals, Synspira Therapeutics Inc., AIT Therapeutics Inc., Polyphor AG, OptiNose Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report
What Are The Key Regional Developments Shaping The Inhaled Antibiotics Market?
North America was the largest region in the inhaled antibiotics market share in 2024. The regions covered in the inhaled antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8738&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model